Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 5/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31435948 | 0.92 | JAK2 (0.43) | JAK2JAK1MAP4K3METCDK9 | |
| SCHEMBL31435941 | 0.82 | AXL (0.32) | JAK2JAK1MAP4K3CDK9CCNT1 | |
| SCHEMBL31435915 | 0.79 | TLR9 (0.37) | METCDK9CCNT1GSK3B | |
| SCHEMBL31435964 | 0.79 | JAK2 (0.39) | JAK2JAK1MAP4K3METCDK9 | |
| SCHEMBL31435991 | 0.77 | TLR9 (0.38) | ALKDYRK1AGSK3BAXL | |
| SCHEMBL31435940 | 0.77 | MET (0.35) | JAK2JAK1MAP4K3METAXL | |
| SCHEMBL31435952 | 0.77 | CHEK1 (0.37) | JAK2ALKDYRK1AGSK3BAXL | |
| SCHEMBL31435985 | 0.74 | KIT (0.47) | ALKDYRK1AGSK3BPAK1 | |
| SCHEMBL31435986 | 0.74 | KIT (0.47) | ALKDYRK1AGSK3BPAK1 | |
| SCHEMBL31435906 | 0.73 | MAP4K1 (0.43) | ALKPAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2025-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | TYRO3, TH, TYR | JAK2 55/4885JAK1 131/4885MAP4K3 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.